We are live on ! Find out more
DOVA

Dova Pharmaceuticals, Inc. Common Stock
DOVA

Delisted

DOVA was delisted on the 11th of November, 2019.

Back to rankings

0 hedge funds and large institutions have $0 invested in Dova Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 72 closing their positions.

New
Increased
Maintained
Reduced
Closed

34.52% less ownership

Funds ownership: 34.52% → 0% (-35%)

100% less funds holding

Funds holding: 72 → 0 (-72)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $278M

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 72

Holders
–
Holders Change
-72
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
72
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Perceptive Advisors
Perceptive Advisors
New York
-$104M
2
Alpine Associates Management
Alpine Associates Management
Florida
-$39.7M
3
BlackRock
BlackRock
New York
-$27.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$16.6M
5
GW&K Investment Management
GW&K Investment Management
Massachusetts
-$9.24M

DOVA Hedge Fund Activity: Q4 2019 in Review

0 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q4 2019, worth a combined $0 — down 100% from $278M a quarter earlier.

Sellers outnumbered buyers: 72 funds closed out of DOVA and 0 opened new positions — a net loss of 72 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Perceptive Advisors, exiting entirely with an estimated $104M sold.

  • 0 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q4 2019, down from 72 in Q3 2019.
  • Funds reported $0 of Dova Pharmaceuticals, Inc. Common Stock stock for Q4 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q4 2019 and 72 closed out, a net change of -72 holders.
  • The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q4 2019 was Perceptive Advisors, an estimated $104M sold.

Based on aggregated 13F filings for Q4 2019.